Literature DB >> 15788130

Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.

Wen-yuan Mai1, Mao-fang Lin.   

Abstract

BACKGROUND: Homoharringtonine (HHT) is a cephalotaxine ester derived from an evergreen tree found wildely throughout southern China, which has antileukemic activities against a variety of acute myeloid leukemic cells. For the sake of illustrating the mechanisms of HHT in the treatment of leukemia, we assessed the effect of HHT on the apoptosis of human chronic myeloid leukemic cell line K562.
METHODS: The apoptosis of K562 cells induced by HHT was analyzed by transmission electron microscopy, agarose gel electrophoresis of DNA, flow cytometry and terminal deoxyribonucleotidyl transferase-mediated dUTP-biotin nick labeling.
RESULTS: Characteristic apoptosis-related features emerged in K562 cells after exposed to HHT at a concentration 0.05-100 microg/ml. Transmission electron microscopy of HHT treated K562 cells displayed chromatin condensation and aggregation under the nuclear membrane, nuclear fragmentation and apoptosis body formation. Typical DNA ladder in agarose gel electrophoresis was observed in the cells exposed to HHT. The cell cycle analysis measured by flow cytometry showed G1 phase cells decreased with the increase of S phase cells while apoptosis was induced by HHT in K562 cells. The percentage of apoptotic cells in K562 cells treated with 50 microg/ml of HHT decreased significantly when pretreated with 1 microg/ml of cycloheximide, 0.05 microg/ml of Actinomycin D respectively.
CONCLUSIONS: HHT has apoptotic effects on K562 cells. The HHT induced apoptosis mainly of the cells in G1 phase and this process required RNA transcription and protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788130

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  10 in total

1.  Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.

Authors:  Liu-Fang Gu; Wang-Gang Zhang; Fang-Xia Wang; Xing-Mei Cao; Yin-Xia Chen; Ai-Li He; Jie Liu; Xiao-Rong Ma
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-09       Impact factor: 4.553

2.  Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Authors:  Lingyun Wu; Xiao Li; Jiying Su; Qi He; Xi Zhang; Chunkang Chang; Quan Pu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-04       Impact factor: 4.553

3.  Essential oil from Siegesbeckia pubescens induces apoptosis through the mitochondrial pathway in human HepG2 cells.

Authors:  Dan Lv; Kai-Wen Guo; Chan Xu; Mi Huang; Si-Jian Zheng; Xin-Hua Ma; Li-Hong Pan; Qiang Wang; Xin-Zhou Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-02-22

4.  Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.

Authors:  JingYan Tang; Yin Liu; Jing Chen; Huiliang Xue; Ci Pan; LongJun Gu
Journal:  Int J Hematol       Date:  2011-04-21       Impact factor: 2.490

5.  Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway.

Authors:  Haina Wang; Rui Wang; Dan Huang; Sihan Li; Beibei Gao; Zhijie Kang; Bo Tang; Jiajun Xie; Fanzhi Yan; Rui Liang; Hua Li; Jinsong Yan
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

6.  Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia.

Authors:  Cuiping Zheng; Xiaoping Cai; Shenghao Wu; Zhen Liu; Yuejian Shi; Wenjin Zhou
Journal:  Pak J Med Sci       Date:  2014 Nov-Dec       Impact factor: 1.088

Review 7.  Homoharringtonine and omacetaxine for myeloid hematological malignancies.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2014-01-03       Impact factor: 17.388

8.  Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study.

Authors:  Xiaorong Ma; Jin Wang; Yan Xu; Wanggang Zhang; Jie Liu; Xingmei Cao; Aili He; Fangxia Wang; Liufang Gu; Bo Lei; Jianli Wang
Journal:  Onco Targets Ther       Date:  2016-06-20       Impact factor: 4.147

9.  HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.

Authors:  Mixue Xie; Qi Jiang; Li Li; Jingjing Zhu; Lixia Zhu; Yanlong Zheng; Xiudi Yang; Mingyu Zhu; Jianai Sun; Wanzhuo Xie; Xiujin Ye
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

10.  Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.

Authors:  Jun Xu; Ting-Ting Lv; Xiao-Fen Zhou; Ying Huang; Dong-Dong Liu; Guo-Lin Yuan
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.